SFPM: The application for the registration and listing license of Clobetasol Propionate Ointment has been accepted

SFPM announced that its wholly-owned subsidiary Harbin SFPM received the "Acceptance Notice" from the National Medical Products Administration regarding the application for the registration and marketing license of Clobetasol Propionate Ointment. Clobetasol Propionate Ointment is suitable for topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older. The company will actively promote the marketing license work for this product and continuously monitor the approval status, fulfilling its information disclosure obligations in a timely manner